Spironolactone and risk of upper gastrointestinal events: Association is unproved [9]

British Medical Journal

Volumn 333, Issue 7566, 2006, Pages 501-

  Dawwas, Muhammad F ^a  

^a ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SPIRONOLACTONE; ALDOSTERONE ANTAGONIST;

GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HELICOBACTER PYLORI; HUMAN; LETTER; LIVER CIRRHOSIS; MORTALITY; PEPTIC ULCER; PRIORITY JOURNAL; RISK ASSESSMENT; HELICOBACTER INFECTION; NOTE; RISK FACTOR;

ALDOSTERONE ANTAGONISTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; RISK FACTORS; SPIRONOLACTONE;

EID: 33748435512     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.333.7566.501     Document Type: Letter

References (5)

1. Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M. Spironolactone and risk of upper gastrointestinal events: population based case-control study. BMJ 2006;333:330-3. (12 August)
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-17
3. Sparrow N, Adlam D, Cowley A, Hampton JR. The diagnosis of heart failure in general practice: implications for the UK National Service Framework. Eur J Heart Fail 2003;5:349-54.
4. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
5. Saad RJ, Chey WD. Peptic ulcer disease in patients with chronic liver disease: looking beyond bugs and drugs. Gastrointest Endosc 2005;62:357-9.